United States Sexually Transmitted Diseases Diagnostics Market Size, Share, Growth, and Industry Analysis, By Disease Type/Pathogen (Chlamydia trachomatis, Neisseria gonorrhoeae (Gonorrhea) , Human Immunodeficiency Virus (HIV) , Human Papillomavirus (HPV) ), By Diagnostic Technology/Type (Laboratory-Based TestsPCR (Polymerase Chain Reaction) ELISA (Enzyme-Linked Immunosorbent Assay) NAAT (Nucleic Acid Amplification Test) Cell Culture , Rapid Point-of-Care (POC) Tests  Lateral Flow Assays Immunochromatographic Tests , Other Technologies Western Blot Direct Fluorescent Antibody (DFA) Flow Cytometry ) and Forecast, 2026-2034

United States Sexually Transmitted Diseases Diagnostics Market Trends

Decentralized Molecular and Home Testing Accelerates

Diagnostic workflows are shifting toward faster molecular platforms capable of generating actionable results within a single clinical encounter. In January 2025, Roche announced FDA clearance and CLIA waiver for cobas liat CT/NG and CT/NG/MG molecular tests, supporting multi-pathogen detection from a single sample. Globally, more than 1 million STIs are acquired every day, reinforcing demand for rapid identification and treatment.

Home testing is simultaneously moving beyond sample-collection-only models. In March 2025, FDA authorized Visby Medical's OTC home test for chlamydia, gonorrhea and trichomoniasis, delivering results in approximately 30 minutes. HPV prevention also affects diagnostic patterns: in 2024, 78.2% of U.S. adolescents aged 13–17 had received at least 1 HPV vaccine dose and 62.9% were up to date, while jurisdiction-level up-to-date coverage ranged from 39.1% to 79.8%.

United States Sexually Transmitted Diseases Diagnostics Market Drivers

Persistent Infection Burden and Expanded Screening

High disease burden continues to support testing volumes across hospitals, laboratories and community settings. CDC reported 38,793 HIV diagnoses during 2024 across the United States and included territories, with males accounting for 80%, people aged 25–34 for 37%, and male-to-male sexual contact for 65%. The South represented 51% of diagnoses. Meanwhile, FDA reported that U.S. syphilis cases increased 80% between 2018 and 2022, from roughly 115,000 to more than 207,000, strengthening the case for broader screening accessibility.

United States Sexually Transmitted Diseases Diagnostics Market Restraints

Screening Gaps and Uneven Preventive Healthcare Access

Uneven healthcare engagement can constrain diagnostic utilization despite substantial infection prevalence. HPV vaccination data illustrate geographic disparities: adolescent up-to-date coverage ranged from 39.1% in Mississippi to 79.8% in Massachusetts during 2024, while nonmetropolitan areas maintained an approximately 11-percentage-point disadvantage versus principal cities for HPV coverage. Such disparities can coincide with fragmented screening pathways, while confirmatory requirements also affect convenience; for example, a positive OTC syphilis antibody result still requires additional testing for diagnosis.

United States Sexually Transmitted Diseases Diagnostics Market Opportunities

OTC Testing and Decentralized Molecular Diagnostics

Regulatory expansion is creating opportunities beyond conventional laboratories. FDA's 2023 authorization of the LetsGetChecked Simple 2 Test established the first authorized chlamydia and gonorrhea diagnostic with at-home sample collection for adults aged 18+, while the 2025 Visby authorization enabled fully at-home testing for 3 infections with results in approximately 30 minutes. These milestones expand testing into privacy-oriented consumer channels and can reduce dependence on clinic-based specimen collection.

Challenges in United States Sexually Transmitted Diseases Diagnostics Market

Confirmatory Testing and Clinical Follow-through

Greater self-testing availability increases the importance of linkage to care. FDA notes that the first OTC syphilis antibody test cannot independently establish diagnosis and requires confirmatory testing. This challenge occurs against a high-burden backdrop: syphilis reports rose approximately 80% between 2018 and 2022, while 2024 HIV diagnoses totaled 38,793 and 60% occurred among people aged 25–44. Diagnostic access therefore must be accompanied by confirmatory workflows, treatment referral and appropriate interpretation.

United States Sexually Transmitted Diseases Diagnostics Market Segmentation

The industry is segmented by disease/pathogen, diagnostic technology, sample type, testing location and end user. HIV leads disease-based revenue at approximately 20.68% in 2026, while laboratory-based tests represent approximately 47.58% of technology revenue.

By Disease Type/Pathogen

HIV is the largest supplied disease category, increasing from USD 595.38 million in 2025 to USD 639.20 million in 2026 and USD 1,128.18 million by 2034, representing a 7.36% CAGR.

Hepatitis B and C is the fastest-growing listed pathogen category at 7.42% CAGR, narrowly exceeding trichomoniasis at 7.41%. Chlamydia reaches USD 1,064.87 million by 2034 at 6.97%, while gonorrhea reaches USD 814.70 million at 7.29%.

By Diagnostic Technology/Type

Laboratory-based tests lead with USD 1,468.92 million in 2026 and are forecast at USD 2,525.76 million in 2034, registering 7.01% CAGR. The category encompasses PCR, ELISA, NAAT and cell-culture approaches.

Other technologies, including Western blot, DFA and flow cytometry, constitute the fastest-growing supplied technology category at 7.54% CAGR. Rapid POC testing expands at 6.87%, from USD 1,017.43 million in 2026 to USD 1,731.22 million by 2034.

By Sample Type

Blood, urine, oral/vaginal/urethral swabs, cervical/vaginal lavage and semen/prostatic fluid constitute the principal specimen categories. Disease and technology totals indicate a 2026 revenue pool above USD 3.08 billion, with molecular workflows increasingly supporting urine and swab processing.

Sample choice depends on pathogen and platform requirements. FDA-authorized home chlamydia/gonorrhea collection includes male urine and self-collected vaginal-swab configurations, expanding specimen collection outside conventional facilities.

By Location of Testing

Laboratory testing remains structurally important, consistent with laboratory technologies generating USD 1,468.92 million in 2026, or approximately 47.58% of supplied technology revenue. Hospitals and diagnostic laboratories benefit from automated high-throughput molecular platforms.

Clinics, public-health centers and home testing represent increasingly decentralized channels. Rapid POC technologies generate USD 1,017.43 million in 2026 and advance at 6.87% CAGR, while FDA-authorized 30-minute home molecular testing strengthens the consumer testing pathway.

By End User

Hospitals, clinics and diagnostic laboratories constitute major institutional users, supported by the USD 1,468.92 million laboratory-testing category in 2026. Government agencies, public-health programs and NGOs additionally support screening among populations with elevated infection exposure.

Home users represent an emerging decentralized customer group. The broader technology pool increases from approximately USD 3.09 billion in 2026 to USD 5.33 billion in 2034, while OTC authorizations are widening access to chlamydia, gonorrhea, trichomoniasis and syphilis screening.

United States Sexually Transmitted Diseases Diagnostics Market Counties Outlook

Northeast

The Northeast represents a mature diagnostic environment characterized by major academic hospitals, reference laboratories and molecular-testing infrastructure. Within the national USD 3,090.17 million 2026 opportunity, laboratory-based technologies account for approximately 47.58%, supporting high-throughput PCR and NAAT adoption in densely populated healthcare markets.

Midwest

The Midwest combines metropolitan laboratory networks with decentralized community-health requirements. Rapid POC technologies represent approximately 32.96% of supplied 2026 technology revenue and are relevant for clinics serving geographically dispersed populations, while national POC revenue rises from USD 1,017.43 million in 2026 to USD 1,731.22 million by 2034.

South

The South carries substantial testing requirements, particularly for HIV. CDC reported 19,785 HIV diagnoses in the South in 2024, equal to 51% of U.S. and included-territory diagnoses. Against national HIV diagnostic revenue of USD 639.20 million in 2026, this epidemiological concentration reinforces testing requirements across hospitals, community clinics and public-health programs.

West

Western states combine large urban diagnostic networks with decentralized testing requirements. The national disease-based total reaches USD 5,381.39 million by 2034, while rapidly expanding technology categories include other technologies at 7.54% CAGR and POC testing at 6.87%, supporting diversified laboratory, clinic and home-testing models.

Top players in United States Sexually Transmitted Diseases Diagnostics Market

• Abbott Laboratories
• Hologic, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation/Cepheid
• Becton, Dickinson and Company
• bioMérieux SA
• Siemens Healthineers
• QIAGEN N.V.
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• OraSure Technologies, Inc.
• QuidelOrtho Corporation
• DiaSorin S.p.A.
• Visby Medical
• LetsGetChecked

Top Two Companies

• Hologic, Inc. Hologic holds a prominent position in molecular STI diagnostics through its Aptima portfolio and Panther platform. FDA listings include Aptima Combo 2 and pathogen-specific molecular assays for chlamydia and gonorrhea. Laboratory-based technologies account for approximately 47.58% of supplied 2026 industry revenue, providing a substantial addressable environment for automated molecular systems. The category expands from USD 1,468.92 million in 2026 to USD 2,525.76 million in 2034. A precise company percentage cannot be derived from the supplied mandatory dataset and is therefore not fabricated.
• Roche Roche is positioned strongly across centralized and decentralized molecular diagnostics. Its cobas liat portfolio includes CT/NG and CT/NG/MG assays, and the company announced FDA clearance with CLIA waiver in January 2025. Rapid POC technologies represent approximately 32.96% of supplied 2026 technology revenue and reach USD 1,731.22 million by 2034. Roche's exact company percentage is not provided in the mandatory dataset and therefore cannot be stated reliably.

Recent Developments in United States Sexually Transmitted Diseases Diagnostics Market

• 2025:FDA authorized Visby Medical's Women's Sexual Health Test, the first OTC test performed entirely at home for chlamydia, gonorrhea and trichomoniasis, with results in approximately 30 minutes.
• 2025:Roche announced FDA clearance and CLIA waiver for cobas liat CT/NG and CT/NG/MG molecular assays, supporting multi-pathogen POC testing from a single sample.

Research Methodology

The analysis uses the supplied 2025, 2026 and 2034 numerical tables as the mandatory primary basis for revenue, segment contribution and CAGR calculations. Shares were calculated directly from supplied totals; for example, laboratory-based tests represent approximately 47.58% of the 2026 technology total, while HIV represents approximately 20.68% of the 2026 disease-based total. External CDC and FDA information was used only for epidemiology, regulatory developments, adoption indicators and contextual validation. No unsupported county, company or subsegment revenue percentages were fabricated where numerical inputs were unavailable.